Why First-Generation Compounds Still Matter in Research
Liraglutide was the first daily-dosed GLP-1 analog to enter clinical research, and much of the foundational GLP-1R pharmacology literature uses it rather than semaglutide. Comparative research between generations benefits from access to the reference compound.
The research-grade peptide is available as Liraglutide 10mg.
The C16 Fatty Acid Modification
Native GLP-1 has a half-life of ~2 minutes. Liraglutide extends this to ~13 hours through a C16 palmitic acid side chain attached via a glutamic acid spacer. The palmitic acid binds circulating albumin:
- Shielding from DPP-IV cleavage
- Reducing renal clearance
- Enabling once-daily dosing
Semaglutide later extended this further with a C18 diacid — producing a 7-day half-life and once-weekly dosing.
Sequence Homology
Liraglutide is 97% homologous with native human GLP-1 — a single amino acid substitution (Lys²⁶→Arg²⁶) plus the fatty acid attachment. The minimal sequence change preserves native-like receptor pharmacology while enabling the half-life extension.
Semaglutide carries additional modifications (Aib substitution at position 8, the extended C18 diacid) that further alter the pharmacokinetic profile.
Research Positioning
Liraglutide earns research utility in specific contexts:
- Daily-dosing research: Where weekly kinetics would obscure dose-response
- Acute pharmacology: The shorter half-life allows cleaner PK studies
- Historical comparison: Matching the foundational GLP-1 clinical literature
- Generational comparison: Vs semaglutide for structure-activity research
LEAD and SCALE Trial Context
The LEAD (Liraglutide Effect and Action in Diabetes) and SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) trials produced the foundational clinical literature. Peak weight effect in SCALE: approximately −8% at 56 weeks at the 3.0mg dose — substantially less than semaglutide's STEP-1 result of −14.9%.
The delta between the two compounds is itself a research question: how much of the improvement comes from the longer half-life vs the sequence modifications?
Handling
Standard lyophilized peptide handling — −20°C long-term, 2–8°C reconstituted, >98% HPLC purity.
For reference-compound GLP-1R research, see Liraglutide 10mg.